Clinical trials: Enthesitis
Rheumatic Joint Disease
Observational Study of Pediatric Rheumatic Diseases: The CARRA Registry
Continuation of the CARRA Registry as described in the protocol will support data collection on patients with pediatric-onset rheumatic diseases. The CARRA Registry will form the basis for future CARRA studies.
- Trial name
- NCT02418442
- Where
- 82 sites in United States, Canada and 3 more
- Volunteers
- 20,000 people
- Sponsor
- Duke University
Spondyloarthritis, Spondylarthropathy
Assessment of SpondyloArthritis Society (ASAS) Classification and Diagnostic Criteria for Early Axial Spondyloarthritis (SpA)
Background: Existing criteria for AS/SpA such as mod. New York, ESSG, or Amor criteria for classification and/or diagnosis of spondyloarthritis have limitations when applied to early disease.
- Conditions
- Spondyloarthritis, Spondylarthropathy, Spondylitis, Ankylosing
- Trial name
- NCT00328068
- Where
- 35 sites in United States, Belgium and 18 more
- Volunteers
- 992 people
- Sponsor
- Charite University, Berlin, Germany
Enthesitis Related Arthritis, Enthesitis Related Arthritis, Juvenile
The Reliability and Validity of the Ankylosing Spondylitis Performance Index (ASPI) in Enthesitis-Related Arthritis
This study assesses the test-retest reliability, construct validity, and minimal detectable change of the Ankylosing Spondylitis Performance Index (ASPI) in assessing the physical function of patients with Enthesitis-related…
- Trial name
- NCT06383195
- Where
- Turkey (Türkiye)
- Volunteers
- 40 people
- Sponsor
- Hacettepe University
Enthesitis Related Arthritis (ERA)
A Study of the Efficacy and Safety of Adalimumab in Pediatric Subjects With Enthesitis Related Arthritis
The purpose of this study is to evaluate the efficacy and safety of adalimumab given subcutaneously every other week (eow) as compared to placebo in pediatric subjects with Enthesitis Related Arthritis (ERA).
- Trial name
- NCT01166282
- Testing
- adalimumab
- Volunteers
- 46 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Juvenile Psoriatic Arthritis, Enthesitis-related Arthritis
Secukinumab Safety and Efficacy in Juvenile Psoriatic Arthritis (JPsA) and Enthesitis-related Arthritis (ERA)
This was a double-blind, placebo-controlled, event-driven randomized withdrawal study to investigate the efficacy and safety of secukinumab treatment in the Juvenile Idiopathic Arthritis (JIA) categories of Juvenile Psoriatic…
- Trial name
- NCT03031782
- Testing
- secukinumab
- Where
- 31 sites in United States, Belgium and 8 more
- Volunteers
- 86 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis
An Efficacy Study of Secukinumab in Plaque Psoriasis Patients With Subclinical Psoriatic Arthritis as Measured by Musculoskeletal Ultrasound
Given the role of IL-17 in the development of entheseal-driven pathology, a therapeutic strategy aimed at blocking IL-17 would be a logical option for the treatment of subclinical enthesitis in psoriasis patients.
- Trial name
- INTERCEPT (NCT04488185)
- Testing
- Secukinumab 300 mg
- Sponsor
- Novartis Pharmaceuticals
Enthesitis Related Arthritis
Yoga Versus Home Exercise Program in Children With Enthesitis Related Arthritis
The aim of this study is to compare the effectiveness of different exercises programs as 'Yoga' and 'Home Exercise' in Enthesitis Related Arthritis.
- Trial name
- NCT03858504
- Testing
- Exercise
- Where
- Turkey (Türkiye)
- Volunteers
- 21 people
- Sponsor
- Pamukkale University
Shear Wave Elastography
SWE to Detect Enthesitis in PsA: Relationship With SIRT2 Expression and Disease Activity
1. To assess the diagnostic utility of shear-wave elastography (SWE), gray-scale (GS) ultrasound, and Power Doppler (PD) in detecting Patellar and Achilles tendinopathy in psoriatic patients with and without arthritis. 2.
- Trial name
- NCT07188688
- Testing
- Musculoskeletal Ultrasound Device
- Where
- Egypt
- Volunteers
- 57 people
- Sponsor
- Assiut University
Psoriatic Arthritis, Psoriasis
The Diagnostic Ultrasound Enthesitis Tool (DUET) Study
Psoriatic arthritis (PsA) is a type of joint disease that can lead to severe joint damage and disability within the first few years of the disease.
- Conditions
- Psoriatic Arthritis, Psoriasis, Non-Inflammatory Rheumatic Conditions
- Trial name
- DUET (NCT04587362)
- Testing
- Musculoskeletal Ultrasound
- Where
- Canada
- Volunteers
- 419 people
- Sponsor
- Women's College Hospital
Psoriatic Arthritis, Enthesitis
EBIO - Enthesitis Biopsy Study
The purpose of this Phase IV study is to determine the effect of secukinumab on total immune cell numbers obtaines by entheseal biopsy in the inflamed human entheses in patients with Psoriatic Arthritis.
- Conditions
- Psoriatic Arthritis, Enthesitis, Biopsy
- Trial name
- EBIO (NCT04887597)
- Testing
- Secukinumab
- Where
- Germany
- Volunteers
- 10 people
- Sponsor
- University of Erlangen-Nürnberg Medical School
Psoriatic Arthritis, Enthesitis
Ultrasound and Shear Wave Elastography Assessment of Entheses in Psoriatic Arthritis
Psoriatic arthritis (PsA) is a chronic inflammatory disease that frequently involves the entheses, where tendons, ligaments, and fascia insert into bone.
- Trial name
- SWE-PsA (NCT07785089)
- Testing
- Grayscale Ultrasonography, Power Doppler Ultrasonography, and Shear Wave Elastography
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Marmara University
Psoriatic Arthritis, Axial Spondyloarthritis
Study of Efficacy and Safety of Secukinumab in Psoriatic Arthritis and Axial Spondyloarthritis Patients With Active Enthesitis Including One Achilles Tendon Site
The purpose of this study was to demonstrate efficacy, including effects on inflammation by magnetic resonance imaging (MRI) assessments, of secukinumab on Achilles tendon enthesitis for up to 1 year with a primary focus at Week…
- Conditions
- Psoriatic Arthritis, Axial Spondyloarthritis, Enthesitis
- Trial name
- ACHILLES (NCT02771210)
- Testing
- Secukinumab
- Where
- 55 sites in Bulgaria, Czechia and 6 more
- Volunteers
- 204 people
- Sponsor
- Novartis Pharmaceuticals
Spondylitis, Ankylosing, SpA
Enthesitis With Ultra Sonography Doppler in Spondyloarthropathies Treated With Infliximab (Study P04440)
Subjects will be given 3 infusions of infliximab according to the label at week 0, 2, and 6. Subjects will be followed for a maximum of 18 weeks or until relapse.
- Trial name
- EUSpA (NCT00686894)
- Testing
- PDUS, Infliximab
- Volunteers
- 7 people
- Sponsor
- Merck Sharp & Dohme LLC
Psoriasis (PsO), Enthesitis
A Prospective Study to Assess the Efficacy of IL-17 Inhibitors on Subclinical Enthesitis in Patients With Moderate to Severe Psoriasis Based on Power Doppler (PD) Ultrasonography (PDUS)
It is an observational, single-center, prospective, exploratory, open-label study to assess the efficacy and safety of IL-17 inhibitors on subclinical enthesitis in patients with moderate to severe psoriasis with subclinical…
- Conditions
- Psoriasis (PsO), Enthesitis, Psoriasis Arthritis, Secukinumab
- Trial name
- NCT06987292
- Testing
- IL-17i
- Where
- 2 sites in China
- Volunteers
- 50 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Pharmacokinetics, Safety Issues
A Clinical Study With Adalimumab Biosimilar
The study aims to evaluate the pharmacokinetic profile, safety profile, and immunogenic potential of adalimumab of a new citrate-free formulation of adalimumab (Adalimumab Richmond) [Test Product] vs.
- Trial name
- NCT06291948
- Testing
- Humira® (adalimumab) AC Pen [Reference Product], Adalimumab Richmond [Test Product]
- Where
- Argentina
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Laboratorios Richmond S.A.C.I.F.
Polyarticular-course Juvenile Idiopathic Arthritis (JIA)
Pediatric Arthritis Study of Certolizumab Pegol
A Multicenter, Open-label Study to Assess the Pharmacokinetics, Safety and Efficacy of Certolizumab Pegol in Children and Adolescents With Moderately to Severely Active Polyarticular-course Juvenile Idiopathic Arthritis (JIA).
- Trial name
- PASCAL (NCT01550003)
- Testing
- Certolizumab Pegol (CZP)
- Where
- 36 sites in United States, Argentina and 5 more
- Volunteers
- 193 people
- Sponsor
- UCB BIOSCIENCES GmbH
Juvenile Idiopahtic Arthritis
Extension Study Evaluating Etanercept in 3 Subtypes of Childhood Arthritis
This is a 8-year extension study in pediatric subjects who have been diagnosed with one of 3 subtypes of Juvenile Idiopathic Arthritis (JIA) [extended oligoarticular JIA, enthestitis related arthritis (ERA), or psoriatic…
- Trial name
- CLIPPER2 (NCT01421069)
- Testing
- etanercept
- Where
- 35 sites in Australia, Belgium and 17 more
- Volunteers
- 109 people
- Sponsor
- Pfizer
Enthesitis
Detection of Subclinical Enthesitis by Ultrasonography
Detection of subclinical enthesitis by ultrasonography
- Trial name
- NCT04209894
- Testing
- Ultrasound
- Where
- Turkey (Türkiye)
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Fatih Sultan Mehmet Training and Research Hospital
Psoriatic Arthritis, Psoriasis
Ultrasound Enthesitis Response in Psoriatic Arthritis
The aim of this observational study will be to recruit 100 Psoriatic Arthritis (PsA) patients beginning on their biologic therapy and asses, both clinically and with the use of ultrasound (US), how enthesitis responds to biologic…
- Conditions
- Psoriatic Arthritis, Psoriasis, Enthesitis
- Trial name
- NCT03955861
- Testing
- adalimumab, Certolizumab, Etanercept
- Where
- United Kingdom
- Volunteers
- 80 people
- Sponsor
- Belfast Health and Social Care Trust
Juvenile Psoriatic Arthritis, Enthesitis Related Arthritis
A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juvenile Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis
The reason for this study is to see if the study drug ixekizumab is safe and effective in children with juvenile idiopathic arthritis (JIA) categories of enthesitis-related arthritis (ERA) (including juvenile onset ankylosing…
- Trial name
- NCT04527380
- Testing
- Ixekizumab, Adalimumab
- Where
- 43 sites in Argentina, Belgium and 10 more
- Volunteers
- 101 people
- Sponsor
- Eli Lilly and Company